Better than CRISPR? Another way to fix gene problems may be safer and more versatile
By Jocelyn Kaiser,
Science
| 06. 01. 2022
Epigenome editing flips genetic on-off switches in mouse studies
Photo by Steve Johnson on Unsplash
Tools such as CRISPR that snip DNA to alter its sequence are moving tantalizingly close to the clinic as treatment for some genetic diseases. But away from the limelight, researchers are increasingly excited about an alternative that leaves a DNA sequence unchanged. These molecular tools target the epigenome, the chemical tags adorning DNA and its surrounding proteins that govern a gene’s expression and how it ultimately behaves.
A flurry of studies in the past few years in mice suggests epigenome editing is a potentially safer, more flexible way to turn genes on or off than editing DNA. In one example described last month at a gene therapy meeting in Washington, D.C., an Italian team dialed down expression of a gene in mice to lower the animals’ cholesterol levels for months. Other groups are exploring epigenome editing to treat everything from cancer to pain to Huntington disease, a fatal brain disorder.
Unlike DNA editing, where the changes are permanent and can include unintended results, epigenomic edits might be less likely to cause harmful offtarget effects...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Julianna LeMieux, Genetic Engineering & Biotechnology News | 04.14.2026
Twenty years ago, Sven Bocklandt, PhD, sought to create a hypoallergenic cat. He had the genetic engineering chops to do it, but the embryology was beyond his capabilities. At a small animal genetic engineering conference, known as TARC (Transgenic Animal...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...